Fondaparinux sodium

Drug Profile

Fondaparinux sodium

Alternative Names: Arixtra; GSK 576428; ORG 31540; Quixidar; SR 90107; SR 90107A; Xantidar

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Developer GlaxoSmithKline
  • Class Anticoagulants; Antithrombotics; Polysaccharides
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute coronary syndromes; Deep vein thrombosis; Myocardial infarction; Pulmonary embolism; Thromboembolism; Unstable angina pectoris; Venous thrombosis

Most Recent Events

  • 12 Sep 2016 Aspen acquires rights for fondaparinux sodium in China, India and Pakistan from GlaxoSmithKline
  • 31 Dec 2014 Fondaparinux sodium licensed to Mylan in USA
  • 10 Sep 2014 Aspen Global and Mylan enter into an agreement under which Mylan will acquire rights to fondaparinux sodium and its authorised generic in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top